RecruitingNCT06625216

Severe Asthma Network Italy

Observatory of Patients with Severe Asthma and Potential Eligible Patients for Treatment with Biological Drugs


Sponsor

Società Italiana di Allergologia, Asma e Immunologia Clinica

Enrollment

5,000 participants

Start Date

Feb 17, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this registry is collecting data of severe asthma patients, recruited by specialized centers, in a real life setting, homogeneously placed on a database management system to follow them over the time. The information recorded will provide: 1. The collection of homogeneous clinical, functional and biologic data of patients with severe asthma in a real life setting. 2. The evaluation of adherence to treatment in real life. 3. The clinical eligibility of patients treated with biologics. 4. The evaluation of patients' clinical response to each treatment. 5. The monitoring of tolerability and safety. 6. The long-term follow up of patients with severe asthma.


Eligibility

Min Age: 13 Years

Inclusion Criteria11

  • signed informed consent and privacy disclaimer;
  • age \> 12 years;
  • diagnosis of severe asthma according to the ERS/ATS criteria:
  • During treatment with:
  • High-dose ICS + at least one addistional controller (LABA, montelukast, or theophylline) or
  • Oral corticosteroids \>6 months/year
  • at least one of the following occurs or would occur if treatment would be reduced:
  • ACT \<20 or ACQ\>1.5
  • At least 2 exacerbations in the last 12 months
  • At least 1 exacerbation treated in hospital or requiring mechanical ventilation in the last 12 months
  • FEV1 \<80% (if FEV1/FVC below the lower limit of normal)

Locations(1)

Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy

Rozzano, Milano, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06625216


Related Trials